Corrigendum

Integrin α6β4 identifies an adult distal lung epithelial population with regenerative potential in mice

Harold A. Chapman, Xiaopeng Li, Jonathan P. Alexander, Alexis Brumwell, Walter Lorizio, Kevin Tan, Arnoud Sonnenberg, Ying Wei, and Thiennu H. Vu

1Department of Medicine, Cardiovascular Research Institute, and Lung Biology Center, UCSF, San Francisco, California, USA.
2The Netherlands Cancer Institute, Amsterdam, Netherlands.


Citation for this corrigendum: J Clin Invest. 2011;121(8):3360. doi:10.1172/JCI59981.

In the author list, Arnoud Sonnenberg’s affiliation was incorrect. The correct information appears above.

The authors regret the error.

Corrigendum

Abrogation of growth hormone secretion rescues fatty liver in mice with hepatocyte-specific deletion of JAK2

Brandon C. Sos, Charles Harris, Sarah M. Nordstrom, Jennifer L. Tran, Mercedesz Balázs, Patrick Caplazi, Maria Febbraio, Milana A.B. Applegate, Kay-Uwe Wagner, and Ethan J. Weiss


Citation for this corrigendum: J Clin Invest. 2011;121(8):3360. doi:10.1172/JCI59854.

The dosage for GW9662 was incorrectly noted in Results, Methods, and the legend for Figure 6. The correct sentences appear below.

Results: We treated a cohort of younger animals for 2 weeks at a dose of 4 mg/kg body weight and found that there was a 31% reduction in the expression of Cd36 (Figure 6F) and a 48% reduction in liver TG content in JAK2L animals treated with GW9662 versus those treated with vehicle (Figure 6G).

Methods: Each day, an aliquot of stock drug was thawed and then resuspended in DMSO/saline at a final concentration of 4 mg/kg body weight in a final volume of 100 μl.

Figure 6 legend: (F) Normalized expression of Cd36 from livers of male control and JAK2L mice after a 2-week treatment with the PPARγ-specific antagonist GW9662 (G) (4 mg/kg) or vehicle (V) (n = 5 for each group).

The authors regret the error.